DOAC, body weight, trough concentration DOAC, lichaamsgewicht, dalspiegel
Conditions
Interventions
Patients will only use the licensed DOACs (Eliquis®, Xarelto® Lixiana® and Pradaxa®) as standard care prescribed by their physician. No intervention will take place, only DOAC trough concentrations wi
Sponsors
Haga Teaching Hospital and
Central Hospital Pharmacy The Hague
Eligibility
Inclusion criteria
Inclusion criteria: - Male or female ≥ 18 years - Treated with a DOAC (rivaroxaban, dabigatran, apixaban, edoxaban) in a therapeutic or prophylactic dosage for at least 5 days - eGFR > 50 ml/min - Is not mentally disabled - Good understanding of the Dutch language - Written informed consent
Exclusion criteria
Exclusion criteria: - The use of relevant co-medication: Ketoconazole, Posaconazole, Voricanazole , Itraconazole , Fluconazole, HIV protease inhibitors, Ticagrelor , Verapamil , Diltiazem (except dabigatran) , Amiodarone , Quinidine, Cyclosporin, Tacrolimus, Clarithromycin, Erythromycin, Carbamazepine, Rifampicin, St John¡¯s wort, Phenytoin phenobarbital
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to investigate the effect of body weight on the trough concentrations of DOACs. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To investigate the effect of body weight on anti-Factor Xa (FXa) activity for apixaban, rivaroxaban and edoxaban. - To investigate the effect of body weight on anti-Factor IIa (FIIa) activity for dabigatran. | — |
Contacts
Public ContactJ.M. Borst
Haga Teaching Hospital, Central Hospital Pharmacy The Hague, The Netherlands
Outcome results
None listed